DexCom trust linked to director sells 4,000 shares

Accepted by SEC EDGAR 08/04/2026 - 04:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

A family trust associated with DexCom Inc. director Mark G. Foletta sold 4,000 shares of common stock in two indirect open-market transactions: 2,000 shares at $80.00 on July 31, 2026 and 2,000 shares at $85.32 on August 3, 2026, pursuant to a pre‑arranged 10b5‑1 Plan adopted by the Foletta Family Trust on March 13, 2026.

Foletta also directly holds 6,331 unvested restricted stock units granted on May 28, 2026, scheduled to vest on the earlier of the one‑year grant anniversary or DexCom’s 2027 annual meeting of stockholders.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares

Net Sell 2 txns

Insider FOLETTA MARK G

Role Director

Sold 4,000 shs ($331K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,000	$85.32	$171K
Sale	Common Stock F1, F2	2,000	$80.00	$160K
Holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 48,852 shares (Indirect, by Trust); Common Stock — 6,331 shares (Direct)

Footnotes (3)

1. F1. On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
2. F2. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
3. F3. Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Key Figures

Shares sold on 2026-08-03: 2000.0000 shares Sale price on 2026-08-03: $85.3200 per share Shares sold on 2026-07-31: 2000.0000 shares +2 more

5 metrics

Shares sold on 2026-08-03 2000.0000 shares Common stock sold indirectly by The Foletta Family Trust on August 3, 2026

Sale price on 2026-08-03 $85.3200 per share Per‑share price for 2,000 DexCom common shares sold on August 3, 2026

Shares sold on 2026-07-31 2000.0000 shares Common stock sold indirectly by The Foletta Family Trust on July 31, 2026

Sale price on 2026-07-31 $80.0000 per share Per‑share price for 2,000 DexCom common shares sold on July 31, 2026

Unvested restricted stock units 6331.0000 units Unvested RSUs granted to Mark G. Foletta on May 28, 2026

Key Terms

10b5-1 Plan, restricted stock units, Trust

3 terms

10b5-1 Plan regulatory

"On March 13, 2026, The Foletta Family Trust ... adopted a 10b5-1 Plan."

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

restricted stock units financial

"Represents unvested restricted stock units which were granted on May 28, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Trust financial

"Shares are held by The Foletta Family Trust DTD 1/30/2015"

A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sales in DexCom (DXCM) did Mark G. Foletta report?

A family trust for DexCom director Mark G. Foletta sold 4,000 shares of common stock in two indirect open‑market transactions, 2,000 shares on July 31, 2026 and 2,000 shares on August 3, 2026, at prices of $80.00 and $85.32 per share, respectively.

Were the recent DexCom (DXCM) insider sales made under a Rule 10b5-1 plan?

Yes. The Foletta Family Trust adopted a 10b5‑1 Plan on March 13, 2026. The 2,000‑share sale at $80.00 on July 31, 2026 and the 2,000‑share sale at $85.32 on August 3, 2026 were executed pursuant to that trading plan.

How many DexCom (DXCM) shares did the Foletta trust sell, and at what prices?

The Foletta Family Trust sold 2,000 shares of DexCom common stock at $80.00 per share on July 31, 2026 and another 2,000 shares at $85.32 per share on August 3, 2026, totaling 4,000 shares sold indirectly through the trust.

What DexCom (DXCM) equity awards does Mark G. Foletta hold after these transactions?

Mark G. Foletta directly holds 6,331 unvested restricted stock units. These RSUs were granted on May 28, 2026 and are scheduled to vest on the earlier of the one‑year anniversary of the grant date or DexCom’s 2027 annual meeting of stockholders.

Is Mark G. Foletta’s DexCom (DXCM) ownership reported as direct or through a trust?

The reported stock sales involve shares held by The Foletta Family Trust, for which he serves as trustee, reflecting indirect ownership. Separately, the filing shows he directly holds 6,331 unvested restricted stock units granted on May 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOLETTA MARK G

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		S		2,000(1)	D	$80	50,852	I	by Trust(2)
Common Stock	08/03/2026		S		2,000(1)	D	$85.32	48,852	I	by Trust(2)
Common Stock								6,331(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

3. Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)